GITNUXREPORT 2026

Specialty Pharmacy Industry Statistics

Specialty pharmacy dominates drug spending and is growing rapidly worldwide.

Rajesh Patel

Team Lead & Senior Researcher with over 15 years of experience in market research and data analytics.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Multiple sclerosis therapies held 12% of U.S. specialty spend in 2023.

Statistic 2

Oncology specialty drugs utilization grew 7.5% in prescription volume in 2023.

Statistic 3

45% of specialty pharmacy fills in 2022 were for autoimmune conditions.

Statistic 4

Hemophilia factor therapies saw 18% utilization increase in specialty channels in 2023.

Statistic 5

GLP-1 agonists for obesity entered specialty pharmacy with 2 million fills in 2023.

Statistic 6

Psoriasis biologics represented 9% of dermatology specialty scripts in 2022.

Statistic 7

Cystic fibrosis modulators like Trikafta accounted for 95% of CF specialty prescriptions in 2023.

Statistic 8

HIV PrEP utilization in specialty pharmacies rose 25% to 1.2 million patients in 2023.

Statistic 9

Growth hormone therapies for pediatric use: 150,000 annual specialty fills in U.S.

Statistic 10

Inflammatory bowel disease (IBD) drugs: 8% of total specialty revenue, 1.8 million patients.

Statistic 11

CAR-T cell therapies dispensed: 1,200 cases across U.S. specialty pharmacies in 2023.

Statistic 12

Hepatitis C cures in specialty: 98% SVR rate, 250,000 treatments completed 2022-2023.

Statistic 13

Pulmonary arterial hypertension (PAH) drugs: 120,000 patients on specialty therapy.

Statistic 14

Transplant immunosuppressants: 400,000 fills monthly in specialty pharmacies.

Statistic 15

Rare disease drugs: over 500 indications covered in specialty formularies 2023.

Statistic 16

Sickle cell gene therapies: first 50 patients treated via specialty in 2023.

Statistic 17

In 2023, the U.S. specialty pharmacy market size was valued at $491 billion, representing 52% of total drug spending.

Statistic 18

Global specialty pharmacy market projected to grow from $550 billion in 2022 to $1,100 billion by 2030 at a CAGR of 9.0%.

Statistic 19

Specialty drugs accounted for 1.5% of all U.S. prescriptions in 2022 but 51% of total pharmacy spending.

Statistic 20

U.S. specialty pharmacy dispensing volume increased by 8.2% year-over-year in 2023, reaching 45 million prescriptions.

Statistic 21

The oncology segment dominated the specialty pharmacy market with a 28% revenue share in 2023.

Statistic 22

Specialty pharmacy revenue in the U.S. grew 12.5% from 2021 to 2022, outpacing traditional pharmacy growth by 3x.

Statistic 23

By 2025, specialty pharmaceuticals are expected to comprise 56% of total U.S. drug spend.

Statistic 24

The specialty pharmacy services market in Europe was valued at €120 billion in 2022.

Statistic 25

U.S. infusion pharmacy segment within specialty grew 15% in 2023 to $85 billion.

Statistic 26

Home delivery specialty pharmacy prescriptions rose 22% in 2022, comprising 35% of total specialty fills.

Statistic 27

Asia-Pacific specialty pharmacy market expected to grow at 11.2% CAGR through 2030.

Statistic 28

In 2023, rheumatoid arthritis drugs represented 14% of specialty pharmacy spend.

Statistic 29

Specialty pharmacy market fragmentation: top 10 providers control 65% of U.S. market share in 2023.

Statistic 30

Projected U.S. specialty drug spend to hit $600 billion by 2027.

Statistic 31

Specialty biologics spending increased 9.8% in 2022 despite patent cliffs.

Statistic 32

Gene therapy prescriptions in specialty pharmacies tripled from 2021 to 2023.

Statistic 33

U.S. specialty pharmacy PBM market share reached 70% in 2023.

Statistic 34

Latin America specialty pharmacy market valued at $25 billion in 2023, growing 13% YoY.

Statistic 35

Orphan drugs accounted for 22% of specialty pharmacy revenue in 2022.

Statistic 36

Digital specialty pharmacy platforms market to reach $15 billion by 2028.

Statistic 37

U.S. specialty pharmacy patients: 40 million in 2023, 12% of population.

Statistic 38

Medicare Part D specialty tier drugs: average out-of-pocket $500 per month for patients.

Statistic 39

Commercial payers cover 85% of specialty drug costs, patients pay 15% copay average.

Statistic 40

65% of specialty patients are female, primarily due to autoimmune prevalence.

Statistic 41

Average age of specialty pharmacy patients: 48 years, with 25% under 18.

Statistic 42

Medicaid specialty spend per enrollee: $4,200 annually in 2022.

Statistic 43

Employer-sponsored plans: 92% prior authorization for specialty drugs.

Statistic 44

Patient adherence rates in specialty: 78% at 6 months for oral oncolytics.

Statistic 45

30% of specialty patients use financial assistance programs.

Statistic 46

Payer denial rates for specialty drugs: 18% initial denial in 2023.

Statistic 47

High-deductible health plans impact: 22% delay in specialty starts.

Statistic 48

Biosimilar adoption: payers save $12 billion annually on specialty switches.

Statistic 49

Patient satisfaction with specialty pharmacies: 87% NPS score average.

Statistic 50

Specialty drug rebates to payers: 45% of list price on average.

Statistic 51

FDA 503A/B compounding rules impact 20% of specialty sterile preps.

Statistic 52

REMS programs cover 85% of high-risk specialty drugs in 2023.

Statistic 53

Biosimilar pathway approvals: 40 new entries expected by 2025.

Statistic 54

Medicare price negotiation: 10 specialty drugs selected for 2026 cuts.

Statistic 55

EU HTA regulations harmonize 60% of specialty assessments by 2025.

Statistic 56

State parity laws: 45 states mandate specialty coverage equivalence.

Statistic 57

DEA controlled substance tracking in specialty: 100% serialization by 2024.

Statistic 58

PBM transparency laws impact 25% of specialty rebate flows.

Statistic 59

Cell/gene therapy regs: FDA approves 12 new in 2023 for specialty.

Statistic 60

International reference pricing affects 15% of U.S. specialty imports.

Statistic 61

Accreditation rates: 95% of specialty pharmacies URAC certified.

Statistic 62

Step therapy exemptions for specialty: granted in 70% appeals.

Statistic 63

Future outlook: precision medicine to drive 20% specialty growth by 2030.

Statistic 64

Telehealth integration: 60% of specialty patients prefer virtual consults.

Statistic 65

AI-driven prior auth approval time reduced to 24 hours in 70% of specialty pharmacies.

Statistic 66

Robotic dispensing in specialty: error rate <0.01%, handling 20% of fills.

Statistic 67

Blockchain for drug traceability implemented in 15% of specialty networks.

Statistic 68

Mobile app adherence reminders boost compliance by 25% in specialty.

Statistic 69

EHR integration rate: 92% of specialty pharmacies fully connected.

Statistic 70

Wearables monitoring for specialty patients: 35% adoption in cardiology.

Statistic 71

Cloud-based inventory management: reduces stockouts by 40% in specialty.

Statistic 72

Predictive analytics for readmissions: 18% reduction in specialty cohorts.

Statistic 73

Virtual specialty pharmacy hubs serve 50% of rural patients.

Statistic 74

RPA for claims processing: 80% faster adjudication in specialty.

Statistic 75

Patient portals access: 88% of specialty patients use daily.

Statistic 76

5G-enabled home infusion monitoring in 10% of specialty programs.

Statistic 77

Cybersecurity incidents in specialty pharmacies: down 30% post-2022 standards.

1/77

Sources

Trusted by 500+ publications

+497

Imagine a sector where just 1.5% of prescriptions account for over half of all drug spending—welcome to the dynamic and data-driven world of the specialty pharmacy industry.

Key Takeaways

In 2023, the U.S. specialty pharmacy market size was valued at $491 billion, representing 52% of total drug spending.
Global specialty pharmacy market projected to grow from $550 billion in 2022 to $1,100 billion by 2030 at a CAGR of 9.0%.
Specialty drugs accounted for 1.5% of all U.S. prescriptions in 2022 but 51% of total pharmacy spending.
Multiple sclerosis therapies held 12% of U.S. specialty spend in 2023.
Oncology specialty drugs utilization grew 7.5% in prescription volume in 2023.
45% of specialty pharmacy fills in 2022 were for autoimmune conditions.
U.S. specialty pharmacy patients: 40 million in 2023, 12% of population.
Medicare Part D specialty tier drugs: average out-of-pocket $500 per month for patients.
Commercial payers cover 85% of specialty drug costs, patients pay 15% copay average.
Telehealth integration: 60% of specialty patients prefer virtual consults.
AI-driven prior auth approval time reduced to 24 hours in 70% of specialty pharmacies.
Robotic dispensing in specialty: error rate <0.01%, handling 20% of fills.
FDA 503A/B compounding rules impact 20% of specialty sterile preps.
REMS programs cover 85% of high-risk specialty drugs in 2023.
Biosimilar pathway approvals: 40 new entries expected by 2025.

Specialty pharmacy dominates drug spending and is growing rapidly worldwide.

Drug Categories and Utilization

Multiple sclerosis therapies held 12% of U.S. specialty spend in 2023.
Oncology specialty drugs utilization grew 7.5% in prescription volume in 2023.
45% of specialty pharmacy fills in 2022 were for autoimmune conditions.
Hemophilia factor therapies saw 18% utilization increase in specialty channels in 2023.
GLP-1 agonists for obesity entered specialty pharmacy with 2 million fills in 2023.
Psoriasis biologics represented 9% of dermatology specialty scripts in 2022.
Cystic fibrosis modulators like Trikafta accounted for 95% of CF specialty prescriptions in 2023.
HIV PrEP utilization in specialty pharmacies rose 25% to 1.2 million patients in 2023.
Growth hormone therapies for pediatric use: 150,000 annual specialty fills in U.S.
Inflammatory bowel disease (IBD) drugs: 8% of total specialty revenue, 1.8 million patients.
CAR-T cell therapies dispensed: 1,200 cases across U.S. specialty pharmacies in 2023.
Hepatitis C cures in specialty: 98% SVR rate, 250,000 treatments completed 2022-2023.
Pulmonary arterial hypertension (PAH) drugs: 120,000 patients on specialty therapy.
Transplant immunosuppressants: 400,000 fills monthly in specialty pharmacies.
Rare disease drugs: over 500 indications covered in specialty formularies 2023.
Sickle cell gene therapies: first 50 patients treated via specialty in 2023.

Drug Categories and Utilization Interpretation

Specialty pharmacies are juggling an ever-expanding catalog of life-changing therapies, from the massive scale of autoimmune treatments to the meticulous, personalized delivery of cutting-edge cures, proving they've become the central nervous system of modern medicine.

Market Growth and Size

In 2023, the U.S. specialty pharmacy market size was valued at $491 billion, representing 52% of total drug spending.
Global specialty pharmacy market projected to grow from $550 billion in 2022 to $1,100 billion by 2030 at a CAGR of 9.0%.
Specialty drugs accounted for 1.5% of all U.S. prescriptions in 2022 but 51% of total pharmacy spending.
U.S. specialty pharmacy dispensing volume increased by 8.2% year-over-year in 2023, reaching 45 million prescriptions.
The oncology segment dominated the specialty pharmacy market with a 28% revenue share in 2023.
Specialty pharmacy revenue in the U.S. grew 12.5% from 2021 to 2022, outpacing traditional pharmacy growth by 3x.
By 2025, specialty pharmaceuticals are expected to comprise 56% of total U.S. drug spend.
The specialty pharmacy services market in Europe was valued at €120 billion in 2022.
U.S. infusion pharmacy segment within specialty grew 15% in 2023 to $85 billion.
Home delivery specialty pharmacy prescriptions rose 22% in 2022, comprising 35% of total specialty fills.
Asia-Pacific specialty pharmacy market expected to grow at 11.2% CAGR through 2030.
In 2023, rheumatoid arthritis drugs represented 14% of specialty pharmacy spend.
Specialty pharmacy market fragmentation: top 10 providers control 65% of U.S. market share in 2023.
Projected U.S. specialty drug spend to hit $600 billion by 2027.
Specialty biologics spending increased 9.8% in 2022 despite patent cliffs.
Gene therapy prescriptions in specialty pharmacies tripled from 2021 to 2023.
U.S. specialty pharmacy PBM market share reached 70% in 2023.
Latin America specialty pharmacy market valued at $25 billion in 2023, growing 13% YoY.
Orphan drugs accounted for 22% of specialty pharmacy revenue in 2022.
Digital specialty pharmacy platforms market to reach $15 billion by 2028.

Market Growth and Size Interpretation

In a startling economic twist, a minuscule 1.5% of prescriptions now commandeer over half the nation's pharmacy budget, proving definitively that in modern healthcare, the cure is far costlier than the disease.

Patient and Payer Insights

U.S. specialty pharmacy patients: 40 million in 2023, 12% of population.
Medicare Part D specialty tier drugs: average out-of-pocket $500 per month for patients.
Commercial payers cover 85% of specialty drug costs, patients pay 15% copay average.
65% of specialty patients are female, primarily due to autoimmune prevalence.
Average age of specialty pharmacy patients: 48 years, with 25% under 18.
Medicaid specialty spend per enrollee: $4,200 annually in 2022.
Employer-sponsored plans: 92% prior authorization for specialty drugs.
Patient adherence rates in specialty: 78% at 6 months for oral oncolytics.
30% of specialty patients use financial assistance programs.
Payer denial rates for specialty drugs: 18% initial denial in 2023.
High-deductible health plans impact: 22% delay in specialty starts.
Biosimilar adoption: payers save $12 billion annually on specialty switches.
Patient satisfaction with specialty pharmacies: 87% NPS score average.
Specialty drug rebates to payers: 45% of list price on average.

Patient and Payer Insights Interpretation

The specialty pharmacy industry is a paradox where patients face $500 monthly bills and 18% denials for vital drugs, yet insurers reap 45% rebates and biosimilars save billions, all while 87% of patients somehow remain satisfied with their care.

Regulations and Future Outlook

FDA 503A/B compounding rules impact 20% of specialty sterile preps.
REMS programs cover 85% of high-risk specialty drugs in 2023.
Biosimilar pathway approvals: 40 new entries expected by 2025.
Medicare price negotiation: 10 specialty drugs selected for 2026 cuts.
EU HTA regulations harmonize 60% of specialty assessments by 2025.
State parity laws: 45 states mandate specialty coverage equivalence.
DEA controlled substance tracking in specialty: 100% serialization by 2024.
PBM transparency laws impact 25% of specialty rebate flows.
Cell/gene therapy regs: FDA approves 12 new in 2023 for specialty.
International reference pricing affects 15% of U.S. specialty imports.
Accreditation rates: 95% of specialty pharmacies URAC certified.
Step therapy exemptions for specialty: granted in 70% appeals.
Future outlook: precision medicine to drive 20% specialty growth by 2030.

Regulations and Future Outlook Interpretation

The regulatory landscape for specialty pharmacy is a tightly wound, high-stakes paradox where nearly every pill, vial, and bag of medicine comes wrapped in a rulebook, yet within this bureaucratic labyrinth, innovation finds a way to sprint and patient access fights to keep pace.

Technology and Operations

Telehealth integration: 60% of specialty patients prefer virtual consults.
AI-driven prior auth approval time reduced to 24 hours in 70% of specialty pharmacies.
Robotic dispensing in specialty: error rate <0.01%, handling 20% of fills.
Blockchain for drug traceability implemented in 15% of specialty networks.
Mobile app adherence reminders boost compliance by 25% in specialty.
EHR integration rate: 92% of specialty pharmacies fully connected.
Wearables monitoring for specialty patients: 35% adoption in cardiology.
Cloud-based inventory management: reduces stockouts by 40% in specialty.
Predictive analytics for readmissions: 18% reduction in specialty cohorts.
Virtual specialty pharmacy hubs serve 50% of rural patients.
RPA for claims processing: 80% faster adjudication in specialty.
Patient portals access: 88% of specialty patients use daily.
5G-enabled home infusion monitoring in 10% of specialty programs.
Cybersecurity incidents in specialty pharmacies: down 30% post-2022 standards.

Technology and Operations Interpretation

The future of specialty pharmacy isn't just arriving in a vial; it's beaming in through wearables, accelerated by bots, secured by blockchain, and preferred by patients who'd rather click than commute, proving that high-tech care is, at its heart, profoundly human touch.

Sources & References

Logos provided by Logo.dev